In another move designed to reduce the US' reliance on imported medicines, the FDA has launched a pilot of fast-track reviews for generics tested and made in domestic facilities. According to the ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ingredient in diabetes therapy Ozempic and obesity drug Wegovy, into the ...

Covering the video games industry since 2017, with experience in news, articles, lists, and reviews (and I blame The Legend of Zelda: Majora's Mask for that). If you are a fan of RPGs and want a third ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...